Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer

I. Rae Cho, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Jae Bock Chung, S. Young Song, Jinsil Seong, H. Kyoung Hwang, ChangMoo Kang, Woo Jung Lee, Jeong Youp Park

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Surgical resection is the only curative treatment for pancreatic cancer, but surgical outcomes for borderline resectable pancreatic cancer (BRPC) are generally poor because of the complexity of the surgery and the advanced nature of the tumor. The aim of this study was to evaluate whether neoadjuvant concurrent chemoradiation therapy (CCRT) in BRPC patients could improve surgical outcome. Methods: Baseline characteristics and treatment outcomes for patients who underwent surgery for BRPC with (CCRT group) and without neoadjuvant treatment (CCRT (-) group) were retrospectively compared. Treatment outcomes measured included overall survival, recurrence-free survival, and perioperative complications. Results: A total of 30 patients were included in the CCRT group and 21 patients in the CCRT (-) group. Baseline characteristics were not different before CCRT, but pathological examination after resection revealed reduced tumor size and a lower neurovascular invasion rate in the CCRTgroup. Overall median survival time was 45.0 months in the CCRTgroup and 23.5 months in the CCRT (-) group (p 0.045). The CCRT group had a lower recurrence rate (50.0% vs. 81.0%; p 0.024) and a longer median disease-free survival period (21.0 months vs. 10.6 months; p0.004) than the CCRT (-) group. Perioperative complication rates were not different between the two groups. Conclusions: Neoadjuvant chemoradiation therapy combined with surgical resection yielded better treatment outcomes in patients with BRPC compared with surgery alone. Further larger prospective clinical trials with well defined enrollment criteria and treatment plan are needed.

Original languageEnglish
Pages (from-to)539-543
Number of pages5
JournalPancreatology
Volume13
Issue number5
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

gemcitabine
Neoadjuvant Therapy
Chemoradiotherapy
Group Psychotherapy
Pancreatic Neoplasms
Survival
Recurrence
Therapeutics
Disease-Free Survival
Neoplasms
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Cho, I. R., Chung, M. J., Bang, S., Park, S. W., Chung, J. B., Song, S. Y., ... Park, J. Y. (2013). Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer. Pancreatology, 13(5), 539-543. https://doi.org/10.1016/j.pan.2013.07.064
Cho, I. Rae ; Chung, Moon Jae ; Bang, Seungmin ; Park, Seung Woo ; Chung, Jae Bock ; Song, S. Young ; Seong, Jinsil ; Hwang, H. Kyoung ; Kang, ChangMoo ; Lee, Woo Jung ; Park, Jeong Youp. / Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer. In: Pancreatology. 2013 ; Vol. 13, No. 5. pp. 539-543.
@article{9088de0a14b44ec7836a688b0f970d2a,
title = "Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer",
abstract = "Background: Surgical resection is the only curative treatment for pancreatic cancer, but surgical outcomes for borderline resectable pancreatic cancer (BRPC) are generally poor because of the complexity of the surgery and the advanced nature of the tumor. The aim of this study was to evaluate whether neoadjuvant concurrent chemoradiation therapy (CCRT) in BRPC patients could improve surgical outcome. Methods: Baseline characteristics and treatment outcomes for patients who underwent surgery for BRPC with (CCRT group) and without neoadjuvant treatment (CCRT (-) group) were retrospectively compared. Treatment outcomes measured included overall survival, recurrence-free survival, and perioperative complications. Results: A total of 30 patients were included in the CCRT group and 21 patients in the CCRT (-) group. Baseline characteristics were not different before CCRT, but pathological examination after resection revealed reduced tumor size and a lower neurovascular invasion rate in the CCRTgroup. Overall median survival time was 45.0 months in the CCRTgroup and 23.5 months in the CCRT (-) group (p 0.045). The CCRT group had a lower recurrence rate (50.0{\%} vs. 81.0{\%}; p 0.024) and a longer median disease-free survival period (21.0 months vs. 10.6 months; p0.004) than the CCRT (-) group. Perioperative complication rates were not different between the two groups. Conclusions: Neoadjuvant chemoradiation therapy combined with surgical resection yielded better treatment outcomes in patients with BRPC compared with surgery alone. Further larger prospective clinical trials with well defined enrollment criteria and treatment plan are needed.",
author = "Cho, {I. Rae} and Chung, {Moon Jae} and Seungmin Bang and Park, {Seung Woo} and Chung, {Jae Bock} and Song, {S. Young} and Jinsil Seong and Hwang, {H. Kyoung} and ChangMoo Kang and Lee, {Woo Jung} and Park, {Jeong Youp}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.pan.2013.07.064",
language = "English",
volume = "13",
pages = "539--543",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",
number = "5",

}

Cho, IR, Chung, MJ, Bang, S, Park, SW, Chung, JB, Song, SY, Seong, J, Hwang, HK, Kang, C, Lee, WJ & Park, JY 2013, 'Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer', Pancreatology, vol. 13, no. 5, pp. 539-543. https://doi.org/10.1016/j.pan.2013.07.064

Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer. / Cho, I. Rae; Chung, Moon Jae; Bang, Seungmin; Park, Seung Woo; Chung, Jae Bock; Song, S. Young; Seong, Jinsil; Hwang, H. Kyoung; Kang, ChangMoo; Lee, Woo Jung; Park, Jeong Youp.

In: Pancreatology, Vol. 13, No. 5, 01.01.2013, p. 539-543.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer

AU - Cho, I. Rae

AU - Chung, Moon Jae

AU - Bang, Seungmin

AU - Park, Seung Woo

AU - Chung, Jae Bock

AU - Song, S. Young

AU - Seong, Jinsil

AU - Hwang, H. Kyoung

AU - Kang, ChangMoo

AU - Lee, Woo Jung

AU - Park, Jeong Youp

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Surgical resection is the only curative treatment for pancreatic cancer, but surgical outcomes for borderline resectable pancreatic cancer (BRPC) are generally poor because of the complexity of the surgery and the advanced nature of the tumor. The aim of this study was to evaluate whether neoadjuvant concurrent chemoradiation therapy (CCRT) in BRPC patients could improve surgical outcome. Methods: Baseline characteristics and treatment outcomes for patients who underwent surgery for BRPC with (CCRT group) and without neoadjuvant treatment (CCRT (-) group) were retrospectively compared. Treatment outcomes measured included overall survival, recurrence-free survival, and perioperative complications. Results: A total of 30 patients were included in the CCRT group and 21 patients in the CCRT (-) group. Baseline characteristics were not different before CCRT, but pathological examination after resection revealed reduced tumor size and a lower neurovascular invasion rate in the CCRTgroup. Overall median survival time was 45.0 months in the CCRTgroup and 23.5 months in the CCRT (-) group (p 0.045). The CCRT group had a lower recurrence rate (50.0% vs. 81.0%; p 0.024) and a longer median disease-free survival period (21.0 months vs. 10.6 months; p0.004) than the CCRT (-) group. Perioperative complication rates were not different between the two groups. Conclusions: Neoadjuvant chemoradiation therapy combined with surgical resection yielded better treatment outcomes in patients with BRPC compared with surgery alone. Further larger prospective clinical trials with well defined enrollment criteria and treatment plan are needed.

AB - Background: Surgical resection is the only curative treatment for pancreatic cancer, but surgical outcomes for borderline resectable pancreatic cancer (BRPC) are generally poor because of the complexity of the surgery and the advanced nature of the tumor. The aim of this study was to evaluate whether neoadjuvant concurrent chemoradiation therapy (CCRT) in BRPC patients could improve surgical outcome. Methods: Baseline characteristics and treatment outcomes for patients who underwent surgery for BRPC with (CCRT group) and without neoadjuvant treatment (CCRT (-) group) were retrospectively compared. Treatment outcomes measured included overall survival, recurrence-free survival, and perioperative complications. Results: A total of 30 patients were included in the CCRT group and 21 patients in the CCRT (-) group. Baseline characteristics were not different before CCRT, but pathological examination after resection revealed reduced tumor size and a lower neurovascular invasion rate in the CCRTgroup. Overall median survival time was 45.0 months in the CCRTgroup and 23.5 months in the CCRT (-) group (p 0.045). The CCRT group had a lower recurrence rate (50.0% vs. 81.0%; p 0.024) and a longer median disease-free survival period (21.0 months vs. 10.6 months; p0.004) than the CCRT (-) group. Perioperative complication rates were not different between the two groups. Conclusions: Neoadjuvant chemoradiation therapy combined with surgical resection yielded better treatment outcomes in patients with BRPC compared with surgery alone. Further larger prospective clinical trials with well defined enrollment criteria and treatment plan are needed.

UR - http://www.scopus.com/inward/record.url?scp=84892620335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892620335&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2013.07.064

DO - 10.1016/j.pan.2013.07.064

M3 - Article

C2 - 24075521

AN - SCOPUS:84892620335

VL - 13

SP - 539

EP - 543

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 5

ER -